Diaz-Rodriguez E, et al. - Given dapagliflozin reduces body fat and cardiovascular events in diabetic patients, researchers herein investigated its impact on epicardial adipose tissue (EAT) and subcutaneous adipose tissue (SAT). Findings demonstrated that dapagliflozin increased glucose uptake, attenuated the secretion of pro-inflammatory chemokines (with a beneficial effect on the healing of human coronary artery endothelial cells), and improved the differentiation of EAT cells. These data suggest a new protective pathway for this drug on EAT from patients with cardiovascular disease.